抗拓扑异构酶I和抗着丝点抗体在系统性硬化症患者中的共存。利妥昔单抗与尼达尼布联合治疗的疗效观察。一份病例报告。

IF 2.6 3区医学 Q3 IMMUNOLOGY

International Journal of Immunopathology and Pharmacology Pub Date : 2022-01-01 DOI:10.1177/03946320221115310

Lydia Montolio-Chiva, Diego Carmona-Talavera, Jose M López-Ortega, Ana V Orenes-Vera, Eduardo Flores-Fernández, Juan J Alegre-Sancho

{"title":"抗拓扑异构酶I和抗着丝点抗体在系统性硬化症患者中的共存。利妥昔单抗与尼达尼布联合治疗的疗效观察。一份病例报告。","authors":"Lydia Montolio-Chiva, Diego Carmona-Talavera, Jose M López-Ortega, Ana V Orenes-Vera, Eduardo Flores-Fernández, Juan J Alegre-Sancho","doi":"10.1177/03946320221115310","DOIUrl":null,"url":null,"abstract":"In the diagnostic of systemic sclerosis (SSc), both anti-centromere (ACA) and anti-topoisomerase I (ATA) antibodies are considered mutually exclusive, though their coexistence has been also reported in some patients. Notably, nintedanib has been approved for the treatment of interstitial lung disease associated to SSc. Herein, we present the clinical case of a 41-year-old woman with SSc who shows an immunological seroconversion (from ACA positivity to a coexistence of ACA and ATA antibodies) together with changes in her clinical phenotype. Besides, the patient responds positively to the treatment of her lung involvement with a combination of immunomodulators and antifibrotic agents.","PeriodicalId":14046,"journal":{"name":"International Journal of Immunopathology and Pharmacology","volume":" ","pages":"3946320221115310"},"PeriodicalIF":2.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/3a/10.1177_03946320221115310.PMC9393658.pdf","citationCount":"0","resultStr":"{\"title\":\"Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report.\",\"authors\":\"Lydia Montolio-Chiva, Diego Carmona-Talavera, Jose M López-Ortega, Ana V Orenes-Vera, Eduardo Flores-Fernández, Juan J Alegre-Sancho\",\"doi\":\"10.1177/03946320221115310\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the diagnostic of systemic sclerosis (SSc), both anti-centromere (ACA) and anti-topoisomerase I (ATA) antibodies are considered mutually exclusive, though their coexistence has been also reported in some patients. Notably, nintedanib has been approved for the treatment of interstitial lung disease associated to SSc. Herein, we present the clinical case of a 41-year-old woman with SSc who shows an immunological seroconversion (from ACA positivity to a coexistence of ACA and ATA antibodies) together with changes in her clinical phenotype. Besides, the patient responds positively to the treatment of her lung involvement with a combination of immunomodulators and antifibrotic agents.\",\"PeriodicalId\":14046,\"journal\":{\"name\":\"International Journal of Immunopathology and Pharmacology\",\"volume\":\" \",\"pages\":\"3946320221115310\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/3a/10.1177_03946320221115310.PMC9393658.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Immunopathology and Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/03946320221115310\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Immunopathology and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03946320221115310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在系统性硬化症(SSc)的诊断中，抗着丝粒(ACA)和抗拓扑异构酶I (ATA)抗体被认为是相互排斥的，尽管它们在一些患者中也有共存的报道。值得注意的是，尼达尼布已被批准用于治疗与SSc相关的间质性肺疾病。在此，我们报告了一名41岁SSc女性的临床病例，她表现出免疫血清转换(从ACA阳性到ACA和ATA抗体共存)以及临床表型的变化。此外，患者对联合使用免疫调节剂和抗纤维化药物治疗其肺部病变反应积极。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report.

查看原文本刊更多论文

Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report.

In the diagnostic of systemic sclerosis (SSc), both anti-centromere (ACA) and anti-topoisomerase I (ATA) antibodies are considered mutually exclusive, though their coexistence has been also reported in some patients. Notably, nintedanib has been approved for the treatment of interstitial lung disease associated to SSc. Herein, we present the clinical case of a 41-year-old woman with SSc who shows an immunological seroconversion (from ACA positivity to a coexistence of ACA and ATA antibodies) together with changes in her clinical phenotype. Besides, the patient responds positively to the treatment of her lung involvement with a combination of immunomodulators and antifibrotic agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Immunopathology and Pharmacology 医学-病理学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

15 weeks

期刊介绍： International Journal of Immunopathology and Pharmacology is an Open Access peer-reviewed journal publishing original papers describing research in the fields of immunology, pathology and pharmacology. The intention is that the journal should reflect both the experimental and clinical aspects of immunology as well as advances in the understanding of the pathology and pharmacology of the immune system.